DAY ONE BIOPHARMACEUTICALS I (DAWN)

US23954D1090 - Common Stock

16.7  +0.91 (+5.76%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (3/28/2024, 3:24:54 PM)

16.7

+0.91 (+5.76%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.46B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DAWN Daily chart

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 133 full-time employees. The company went IPO on 2021-05-27. The firm is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The firm seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. The company has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.

Company Info

DAY ONE BIOPHARMACEUTICALS I

2000 Sierra Point Parkway, Suite 501

Brisbane California CALIFORNIA

P: 16504840899

CEO: Jeremy Bender

Employees: 133

Website: https://dayonebio.com/

DAWN News

News Image6 days ago - Market News VideoCommit To Purchase Day One Biopharmaceuticals At $12.50, Earn 52.8% Annualized Using Options
News Imagea month ago - Seeking AlphaDay One Biopharmaceuticals reports Q4 results (NASDAQ:DAWN)

Day One Biopharmaceuticals reported a Q4 net loss of $54.5 million and ended 2023 with $366.3 million in cash, ensuring financial stability until 2026.

News Imagea month ago - Day One Biopharmaceuticals, Inc.Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
News Imagea month ago - Day One Biopharmaceuticals, Inc.Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational...

News Image2 months ago - Day One Biopharmaceuticals, Inc.Day One Announces Two New Appointments to Board of Directors
News Image3 months ago - Market News VideoInteresting DAWN Put And Call Options For February 2024

DAWN Twits

Here you can normally see the latest stock twits on DAWN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example